DNA Repair data presented at American Academy of Dermatology Meeting
First results of afamelanotide in xeroderma pigmentosum C (XPC) presented to Photodermatology...
Read More
Statement on Silicon Valley Bank (SVB)
Melbourne, Australia, 13 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
News Communiqué I - Maestro Jaap van Zweden
Introducing CLINUVEL Intriguing Personality (CUVIP), Maestro Jaap van Zweden.
Read More
Commercial Update SCENESSE®
CLINUVEL today published its 2022 status report on the commercial distribution of...
Read More
Relief from Quarterly Reporting
Melbourne, Australia, 2 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
CLINUVEL launches CYACÊLLE, Next Generation Solar Care
Melbourne, Australia, 01 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
CYACÊLLE Polychromatic Solar Care – λ3
Melbourne, Australia, 01 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Proposed issue of Securities
Melbourne, Australia, 28 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings
Melbourne, Australia, 24 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Appendix 4D Half Yearly Report
Melbourne, Australia, 24 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
PRÉNUMBRA® Formulation Completed For Clinical Trial Use
CLINUVEL today announced the completion of manufacture of the first cGMP batch...
Read More
Chair's Letter
Melbourne, Australia, 09 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Afamelanotide Significantly Reduces UV Skin Damage in a Healthy Population - Technical Note
Melbourne, Australia, 02 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals
Results released today from a clinical study have shown that the drug...
Read More